Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance

Trial Profile

Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Therapeutic Use
  • Acronyms GANCIMVEAR
  • Most Recent Events

    • 12 Aug 2016 Planned End Date changed from 1 Mar 2018 to 1 Apr 2019.
    • 12 Aug 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2018.
    • 12 Aug 2016 Planned initiation date changed from 1 Mar 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top